o2h-ventures

Spun-out from the University of Cambridge in 2016, we use proprietary protein purification and engineering technology to make recombinant proteins in E.coli. Their proteins are properly folded, free from contaminating related TGF beta family proteins (unfortunately often present in mammalian protein expression systems) and they include full QC data for every batch – mass spec, analytical reverse phase, recovery, SDS-PAGE, bioassay data and endotoxin testing.

Use innovative protein engineering techniques to tackle fundamental biological and scalability challenges, such as protein stability and cell culture reproducibility
Status Active
Website https://qkine.com/
Category Pharmaceutical Enabler
Modality Biological & Cell
Therapautics Area Multi Therapautics
Headquaters Cambridge, UK
Partner Precision Life
Investment Portfolio Fund Investment
Co-Investors Cambridge Enterprise, Business Angels Meltwind